Articles Posted in Zantac

Bladder cancer has recently become the focus of the ongoing Zantac lawsuit. In this post, we will look at bladder cancer in personal injury lawsuits.

We examine the nature of bladder cancer as a disease and as an injury in medical malpractice, product liability, and other types of tort cases. Our lawyers also discuss the settlement compensation amounts for bladder cancer in tort cases.

Bladder cancer has become a focus of the Zantac lawsuit because the science linking bladder cancer and NDMA is probably stronger for Zantac than any other cancer.  These may be the strongest of the five cancers that are being pursued in the Zantac class action lawsuit. So there is a new focus on Zantac bladder cancer lawsuits than we saw earlier in the litigation.

The Zantac cancer litigation in the class action MDL in federal court is essentially over after the MDL Judge ruled that the plaintiffs’ scientific evidence on causation was unreliable and, therefore, inadmissible. That could have been the end of the Zatnac lawsuits, but it wasn’t. Since the end of the federal court MDL, the focus of the Zantac litigation has shifted to state courts. A large number of Zantac cancer lawsuits have been consolidated into a state court version of an MDL in Pennsylvania.

This page will explain how the Zantac cancer lawsuits got started in the first place, and look back at the steps we took to get here.

Here is a timeline of events:

The Zantac litigation continues to move forward in state court. The Zantac state court litigation will have a slightly more narrowed focus compared to the initial class action MDL in federal court. The Zantac litigation will focus more on specific types of cancer that have the strongest evidence linking them to NDMA and Zantac use.

• What is the expected individual settlement payout in the Zantac lawsuit

What kind of cancer does NDMA cause?